RxDoctor Payments Data

Abioseh Pieh

Psychiatric/Mental Health · Bear, DENPI 1982330312

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 96.0% of the total across 61 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 27.9% of the total.

$2,008in general payments, 2019–2025

Across 61 payments — averaging $32.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$561
  • Otsuka America Pharmaceutical, Inc.$327
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$189
  • Alkermes, Inc.$182
  • Vanda Pharmaceuticals Inc.$175
  • Teva Pharmaceuticals USA, Inc.$140
  • plus $435 from 9 others

What the payments were for

  • Food & beverage$1,92996%
  • Education$804%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,008 in reported general payments places this provider in the 70th percentile of 177 psychiatric/mental health providers in Delaware.

See all psychiatric/mental health providers in Delaware

Medicare billing

Part B allowed, 2024
$7,273
Medicare patients
25
Services billed
186

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl12$1,313
Fluvoxamine Maleate17$525
Lamotrigine16$265
Duloxetine Hcl17$235
Clonazepam18$226
Quetiapine Fumarate21$210
Aripiprazole13$147
Haloperidol17$112
Atorvastatin Calcium16$96
Lisinopril17$93
Amlodipine Besylate19$87
Omeprazole11$58
Metoprolol Succinate11$43
Trazodone Hcl13$43
Hydrochlorothiazide12$34

Paid to pharmacies, not to this prescriber.

Other psychiatric/mental health in Bear

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →